As the role for adaptor proteins constantly proliferates, appreciation of their importance has never been higher. The Crk family of adaptor proteins is no exception. Currently comprising four members, v-Crk, CrkI, CrkII and Crk-like protein, we have introduced a fifth member, CrkIII. Cloned by the CORT technique, CrkIII is identical in sequence to CrkII until the second of its two SH3 domains, which is disrupted partway through and results in a nonfunctional domain and a unique C-terminal sequence. We have demonstrated the existence of native CrkIII at the message level using RT-PCR and RNAse protection assays, and at the protein level in mouse fibroblasts. We show that CrkII overexpression is capable of enhancing insulin-stimulated ERK activity, whereas CrkIII is not, thus partially characterizing a novel member of the Crk family and elucidating important effects mediated by the c-terminal SH3 domain.
Introduction
As the importance of multi-subunit complexes has emerged in diverse pathways ranging from receptorlinked signalling to transcriptional regulation, an important emphasis has been placed on understanding how these complexes are formed (Feller, 2001 ). While many proteins are able to interact directly with targets/ substrates/cofactors, etc., many other proteins rely on interactions mediated by a type of molecule known as the adaptor protein. The common theme of adaptor proteins is that they serve to bring two or more proteins together by utilizing one or more of many different binding domains, while having no enzymatic properties themselves. One such adaptor protein is Crk, a family of four previously known members. Originally identified as an oncogenic product of the avian sarcoma virus CT10 (Mayer et al., 1988) , mammalian homologues were then identified and found to contain an SH2 domain and either one (in the case of CrkI) or two (in the case of CrkII) SH3 domains (Matsuda et al., 1992) . Crk-like protein (CRKL) is another subsequently discovered family member with high homology in the SH2/SH3 domains and a similar overall structure. The Crk family has been well documented to play diverse roles in growth factor, cytokine and integrin signalling (Feller, 2001) , displaying its adaptor properties in multiple pathways. Among the molecules shown to bind the Crk SH2 domain are paxillin, p130Cas (both known to localize to focal adhesions), IRS-1 and its homologous proteins and c-Cb1 (Birge et al., 1993; Sakai et al., 1994; Beitner-Johnson et al., 1996; Fukazawa et al., 1996; Feller, 2001) . The N-terminal SH3 domain has been demonstrated to bind C3G, DOCK180, Ab1 kinase and possibly PI 3-kinase (Fukui et al., 1989; Knudsen et al., 1994; Matsuda et al., 1994; Tanaka et al., 1994) . CrkII also has a tyrosine residue at position 221, which has been postulated to play an important role in intramolecular regulation of activity, analogous to the model long proposed for the Src family kinases (Xu et al., 1997) . Recently, and for the first time, a protein has been shown to bind Crk within the c-terminal SH3 domain (Smith et al., 2002) . This protein, Crm1, is a nuclear export factor, which results in Crk being excluded from the nucleus under normal circumstances. We propose the addition of a new member of the Crk family, that we have called CrkIII. CrkIII was cloned from a bacterial expression lExlox library of 16-day mouse embryo, using the cloning of receptor targets (CORT) technique (Skolnik et al., 1991; Lowenstein et al., 1992; Margolis et al., 1992) , with phosphorylated carboxyterminal of the EGF receptor as bait. CrkIII has a disrupted Cterminal SH3 domain, believed to be a result of splicing, which maybe able to shed some light on the hitherto unknown function of this particular domain.
Results

Cloning and identification of CrkIII
Using the CORT technique , it is possible to clone proteins containing SH2 domains by virtue of their binding to autophosphorylated growth factor receptors. The bacterial expression lExlox library of 16-day mouse embryo (Novagene) was screened with the tyrosine phosphorylated carboxyterminal tail of the EGF receptor. A clone encoding the full-length sequence of mouse c-CrkII was isolated as well as a novel member of the Crk family which we have designated CrkIII. Figure 1 shows schematic representations of the entire Crk family and the aminoacid sequence of murine CrkII and CrkIII, which are identical up to and including the valine at position 260. An intriguing feature of the CrkIII sequence is a prolinerich region almost at the C-terminus (276-281). This particular sequence (PXXP) fits exactly a motif demonstrated to bind SH3 domains (Feng et al., 1994) .
Existence of CrkIII at message and protein level Figure 2 shows the existence of CrkIII as a message via two different techniques and also shows that this message is capable of being translated into a full-length protein. Reverse transcriptase PCR performed on mouse polyA RNA from various tissues shows three distinct products in each tissue, depending on the combination of primers used (Figure 2a ). Sequencing performed with Sequenase (US Biochemicals) confirmed the identity of these three bands as fragments of CrkI, CrkII and CrkIII. In the left-hand lane of each tissue, two bands are seen. The larger of the two corresponds to the amplified fragment of CrkII and the smaller corresponds to the amplified fragment of CrkI. The same 5-prime end primers were used in all the three reactions. However, whereas CrkI and CrkII have the same 3-prime end sequence, yielding two bands from the same reaction, CrkIII has unique C-terminal sequence, requiring different primers. Panel b of Figure 2 shows an RNAse protection assay, designed to confirm the result seen in panel a and also to establish a more quantitative analysis of the levels of CrkII and CrkIII messages in the mouse polyA RNA. CrkII seems to be much more abundant than CrkIII at the message level, but in certain tissues, for example, lung, smooth muscle and spleen, the ratio between the two would appear to narrow considerably. Panel c shows an autoradiograph of an 35 S-labelled in vitro transcription and translation product for both CrkII and CrkIII. They are both running at the correct predicted molecular weights of approximately 34 and 31 kDa, respectively. We also developed a peptide-derived antibody to the unique C-terminal of the CrkIII protein and screened 20 mg total protein from various mouse tissues by Western blotting. We discovered a band corresponding to the correct molecular weight of CrkIII in mouse Swiss 3T3 fibroblasts (Panel d, lane A) but were only able to see endogenous CrkIII in mouse brain, heart or kidney when 100 mg total protein was loaded in Panel E2 (50 mg of Swiss3T3 lysate was loaded in this panel). In order to verify that the band we saw was specific, and CrkIII, we blotted the same samples with preimmune serum from the CrkIII antibody preparation. The resulting Panel E1 shows no unspecific reactivity in any of the tissues tested, allowing us to confirm that what we are seeing is endogenous CrkIII.
Effect of Crk on ERK activity in L6 and L6C6 cells L6C6 cells, stably overexpressing CrkII, were treated with 0.85 mm insulin for various time intervals and the effect on ERK activity measured by Western blot analysis with phosphorylation-state-dependent anti-ERK antibodies. Figure 3a shows ERK activity markedly increasing in L6C6 cells compared with normal L6 cells after insulin treatment. The control blotting with anti-ERK antibodies shows the identical expression of ERK kinases in L6 and L6C6 cells (Figure 3a, lower panel) . This result, demonstrating the enhancement of insulin-stimulated ERK activity by overexpression of CrkII, meant that we could use this as a marker to investigate and compare the function of CrkIII. The result of transient overexpression of CrkII and CrkIII, as well as a C-terminal mutant of CrkII, W275 K, can be seen in Figure 3b . It supports the observation made in Figure 3a , as ERK activity (as measured by luciferase activity and normalized for transfection efficiency between conditions by b-galactosidase activity) is enhanced by transfection with CrkII. Transfection with both CrkIII and W275 K had no effect on ERK activity in L6 cells beyond control levels. Higher basal levels of active ERK in this assay are due to transfection with the Crk isoforms and reporter constructs for 24 h prior to stimulation, the product of which, luciferase, is cumulative and stable over that period. The effect of Crk overexpression on JNK was also measured using the PathDetect method and neither CrkII nor CrkIII had any effect on insulin-mediated JNK activity. Thus, we conclude that the effect of Crk on Elk phosphorylation is ERK specific and JNK Cells were serum-starved for 24 h and then transfected with 500 ng of pcDNA, CrkII, CrkIII or W275 K and serum-starved for a further 24 h before stimulation with 0.85 mm insulin for 6 h. Cells were lysed using Promega's luciferase activity measurement kit and 20 ml analysed for luciferase activity by luminometry. White bars represent no stimulation; black bars represent 6-h stimulation with 0.85 mm insulin. Results were normalized by cotransfection of a b-galactosidase-expressing plasmid and subsequent measurement of ONPG hydrolysis, leading to an arbitrary value for light units Figure 4 The effect of Ras mutants on Crk-enhanced insulinstimulated ERK signalling. L6 cells were transfected with 100 ng CrkII and DN Ras mutant ranging in dose from 250 ng to 1 mg. Where cotransfections were made, DNA concentrations were not equalized. As per Figure 3 , cells were serum-starved for 24 h before and after transfection, stimulated for 6 h with 0.85 mm insulin, lysed and 20 ml assayed for luciferase production. White bars represent no stimulation; black bars represent 6-h stimulation with 0.85 mm insulin. Results were normalized by cotransfection of a bgalactosidase-expressing plasmid and subsequent measurement of ONPG hydrolysis, leading to an arbitrary value for light units 
Effect of Ras mutants and Crk on insulin-stimulated ERK activity
A dominant-negative (DN) construct of Ras was used in order to investigate the nature of Crk's enhancement of ERK activity. Figure 4 shows clearly that titration of increasing doses of DN Ras can completely inhibit the ability of CrkII overexpression to stimulate ERK activity in an insulin-dependent manner in L6 rat myoblasts. It was previously shown that expression of DN Ras completely inhibited insulin-induced activation of ERK2 in A14 cells (Vries-Smits et al., 1992) and our data clearly support this observation. It is generally accepted that the adaptor protein Grb2 links the insulin receptor to the Ras signalling pathway via interaction of the Grb2-Sos complex, with the docking protein IRS-1 and adaptor protein Shc in insulin-stimulated cells (Skolnik et al., 1993; Smith et al., 2000) . We have previously shown that CrkII is capable of interacting with IRS-1 in L6 rat myoblasts. Furthermore, guanine nucleotide exchange factors Sos1 and C3G are both coprecipitated with CrkII (Okada et al., 1998) . It should be noted that relative light units are not comparable between the experiments, as results within one experiment are normalized for b-galactosidase activity, which is a function of transfection efficiency and which varies between experiments.
Effect of CrkII and CrkIII on insulin-stimulated ERK signalling in L6 and human mesangial cells
In both cell lines, it appears that CrkII overexpression is capable of enhancing insulin-stimulated ERK activity over the 6 h period of stimulation. Panel 5a shows the effect of overexpression in L6 cells and Panel 5b shows the effect in human mesangial cells. Conversely, CrkIII overexpression is incapable of causing the same effect and results in no difference in ERK activity compared to control conditions. In order to show that the relative RNA levels of Crk isoforms were similar in these experiments to the ratios seen in the RNAse protection assay on mouse tissues, Panel 5c shows a typical RNAse protection assay performed on L6 rat myoblasts prior to stimulation with insulin. The figure clearly shows the existence of both CrkII and CrkIII messages by the existence of the 115-base and 95-base (respectively) fragments of RNA. Although identical amounts of DNA were transfected into these cells, the relative amounts of RNA are comparable with those seen in mouse polyA RNA with CrkII message being several fold in excess of that of CrkIII.
Adenoviral-mediated transfer of Crk isoforms, prolongation of insulin-stimulated P42 ERK activity in human mesangial cells
Overexpression of CrkII and CrkIII by adenovirally mediated transfer results in a prolongation of ERK activity (primarily P42 ERK), where CrkII is overexpressed but not where CrkIII is overexpressed. What is clear is that where CrkII is overexpressed, there is a higher level of ERK activity remaining at 15 min of stimulation with insulin, whereas where CrkIII is overexpressed, ERK activity returns to levels similar to control lanes. It does not appear that Crk overexpression affects actual levels of active ERK protein because at 5 min of insulin stimulation, all lanes appear to contain equal levels of active protein. Rather, the presence of high levels of CrkII seems able to retard the return of ERK to an inactive form. Although the difference at 15 min is clear, it is not a large difference. However, when taken in context of the PathDetect data, it demonstrates that small differences in activation at any given time point are capable of manifesting themselves as much larger differences over a longer period, supporting the observation made using the reporter assay in Figure 5 . The overexpression of CrkIII, unable to increase ERK activity alone, does not appear to have any effect on CrkII's ability to prolong ERK activity when coinfected, in support of the observations made of ERK activity in the reporter assay. Panel d supports this data by showing the fold increase in intensity of the phospho-P42 ERK bands compared to the control point at the 15-min time point. Where CrkII is overexpressed, an average of a 2.5-fold increase in ERK activity is seen compared to control levels. Panel c shows that total amounts of P42 ERK were identical in all lanes at the 15 min time point, where the differences in activation were observed. Blots for CrkII and CrkIII overexpression, were made with an antibody that, made to a region common to both CrkII and CrkIII, recognizes both the isoforms.
Discussion
The new member of the Crk family of adaptor proteins, CrkIII, clearly functions in a different role than CrkII. One hypothesis for the mechanism of action of CrkIII is similar to the accepted model for the Src family of tyrosine kinases (Xu et al., 1997) . CrkII has a tyrosine residue at position 221 which, when phosphorylated, could bind the CrkII's own SH2 domain in a selfnegatively regulatory manner by concealing the Nterminal SH3 domain. If the SH2 domain of CrkIII somehow competes for binding of this tyrosine residue, then perhaps CrkII would be free to open out, reexposing its N-terminal SH3 domain, important in downstream signalling. However, the data presented clearly show that CrkIII coexpressed with CrkII is not able to enhance the effect of CrkII alone, ruling out this theory at least under these experimental conditions. Conversely, the fact that coexpression of CrkIII with CrkII did not reduce the effect of CrkII on ERK activity suggests that neither is CrkIII competing for up or downstream targets with CrkII. Recent searches of mouse genome sequences have turned up the origin of the CrkII and CrkIII proteins. In the mouse, both genes appear on chromosome 11, and the C-terminus of CrkII, following the point of divergence from CrkIII, is spliced from approximately 11 kb away on the same chromosome. The C-terminus of CrkIII runs continuously through the point of divergence to its stop codon. It should be noted that the N-terminus of both proteins also appears to be spliced into the final protein as the region of the chromosome encoding both proteins is missing approximately 250 bases at the N-terminus. Thus, it would appear that CrkII is a spliced form of the Crk gene and lack of this splicing event results in the production of CrkIII, perhaps controlled by the mechanisms mentioned previously. In humans, we hypothesize that an almost identical situation occurs on chromosome 17p13.3.
Early work by Matsuda and Tanaka (Matsuda et al., 1992; Tanaka et al., 1993) showed clearly the importance of the first two domains in transformation and neurite differentiation. The same work implies that the inclusion of the C-terminal SH3 domain in CrkII inhibits transformation. More recent work by the Hanafusa laboratory (Akagi et al., 2000) expands this by showing that the SH2 domain of v-Crk is required for protein phosphorylation in cells, but that the SH3 domain is required for efficient transformation. Based on this work, we may have expected CrkIII to revert to a more potent role in the activation of MAP kinase. This is obviously not the case with ERK, but interestingly, further searches of mouse genome sequences provided not only more evidence of the existence of CrkIII at the cDNA level, but again stimulates the question as to the relevance of the C-terminal SH3 domain. cDNA was created from RNA taken from mouse lung tumors and among the cDNA created was a large sequence exactly corresponding to that of CrkIII inclusive of the Cterminus. While not providing existence at the protein level, the discovery of CrkIII cDNA in these mouse lung tumor samples certainly warrants further investigation to elucidate any role the production of CrkIII and its lack of C-terminal SH3 domain may have in the onset or progression of these tumors.
Recent work implicates Crk as an essential component in apoptosis in Xenopus oocytes (Smith et al., 2002) . This work identified the first protein known to bind within the C-terminal SH3 domain of CrkII, a known nuclear export factor Crm1/exportin. Under normal conditions, this protein bound to a region contained within the C-terminal SH3 domain of Crk, shuttling it from the nucleus and preventing a Weel (nuclear cell cycle regulatory protein)-mediated apoptotic fate (Smith et al., 2000) . The amino acids shown to be crucial for Crm1 binding are just after the point of sequence divergence between CrkII and CrkIII, and hence CrkIII lacks them. This could explain provisional results (not shown) indicating that CrkIII has a nuclear localization in human mesangial cells and certainly prompts the intriguing question of whether CrkIII may be made only in cells that are to be diverted to an apoptotic fate. Switching CrkII production to CrkIII by altering splicing during apoptosis could explain low levels of CrkIII seen in normal mouse tissues. A potential role for CrkIII as a mediator of apoptosis is an intriguing and clearly very important possibility.
The existence of message for Crk members I-III in all mouse tissues examined, as shown by reverse transcriptase PCR, raises interesting questions as to the transforming qualities of CrkI. Demonstrated to be transforming in rat 3Y1 cells, its presence is puzzling. Perhaps, levels of CrkI are controlled transcriptionally or translationally, or perhaps there may be some interaction between Crk family members, which controls activity either positively or negatively other than in the ERK activation we have examined here. CrkIII would have to be examined for its ability to transform before any conclusion could be drawn about the effect of the C-terminal SH3 domain in this respect. The existence of all the three messages concurrently would suggest that each might have its own unique function. Whether that function is in a signalling role or regulatory remains to be seen. Whatever the potential for transformation by CrkIII might be, what is clear is that we have cloned, sequenced and partially characterized a new member of the Crk family, with distinct properties and capabilities from those of other family members.
Materials and methods
Cloning of mouse c-CrKIII
Bacterial expression lExlox library of 16-day mouse embryo (Novagene) was screened with the tyrosine phosphorylated carboxyterminal tail of the EGF receptor and sequencing of positive clones was done with Sequenase (US Biochemicals). The clones encoding the full sequence of mouse CrkII and a new member of Crk family of proteins (termed CrkIII) were used in experiments described below.
Oligonucleotide-directed mutagenesis of murine CrKII cDNA A point mutation was introduced into the cDNA of CrkII by oligonucleotide-directed mutagenesis, which replaced Trp-275 with lysine. This mutant is subsequently referred to as W275 K. The template for mutagenesis was prepared by cloning CrkII cDNA into pGEM-7Zf(À) vector (Promega) in the sites KpnI and HindIII. Single-stranded DNA was generated according to the manufacturer's protocols and mutagenesis was carried out using Sculptor in vitro Mutagenesis System (Amersham Pharmacia Biotech) with the oligonucleotide 5 0 -CACTCCCCTTCCTTCTGACCACT-CAC-3 0 , designed to introduce the desired mutation. The mutation was confirmed by DNA sequencing.
Cell culture
The development of the L6C6 cell line was described previously . L6C6 is a cell line overexpressing mouse CrkII. Regular L6 rat myoblast cells and the L6C6 cell line were cultured in Dulbecco's modified Eagle's medium containing 100 U of streptomycin/ml and 100 U penicillin/ml, supplemented with 10% fetal bovine serum. Human glomerular mesangial cells (Sraer et al., 1996) were cultured in RPMI containing 100 U of streptomycin/ml and 100 U penicillin/ml supplemented with 10% fetal bovine serum.
Transfection and PathDetect assays
ERK activity was measured using the PathDetect kit from Stratagene. This involves the measurement of luciferase production, driven by phosphorylated Elk, the downstream transcription factor target of ERK. Transient transfections were performed on 80% confluent cells in six-well dishes using the Lipofectamine Plus system from Gibco. A volume of 100 or 500 ng (as indicated in figure legend) of CrkII and/or CrkIII were transfected into serum-starved (0.25% serum for 24 h) cells. In all, 1 mg of the luciferase construct plasmid and 50 ng of the Elk transactivator plasmid were used in each transfection. Cells were stimulated with 0.85 mm insulin for 6 h in the PathDetect assays, or for the time points indicated in the case of Figure 2 . Results were normalized by concomitant transfection of 1 mg of a plasmid encoding b-galactosidase. Cells were lysed and luciferase activity measured using a luciferase activity system kit from Promega. Out of a 300 ml total lysis volume, 20 ml per well was assayed for luciferase production. Bars shown represent means 7s.e.m. from at least three different experiments.
Coupled reverse transcription and PCR amplification (RT-PCR)
The Promega Access RT-PCR system was used to detect RNA transcripts corresponding to members of the Crk family. The Stratagene Dihydrofolate Reductase Set for RT-PCR (mouse) was used as a positive control. Downstream oligonucleotide primers were designed to anneal specifically to either CrkII (DRC2-1: 5 0 -CATCTGTCAGCAACTGTCGAGCTAT) or CrkIII DRC3-1: 5 0 -CGTTTCGCTGTATCAGCATTCCTAC) transcripts, whereas the upstream oligonucleotide primer was designed to anneal to the sequence identical in CrkII and CrkIII (URC3-1: 5 0 -AGGCAGGGTAGTGGAGTGATTCT-CA). Mouse skeletal muscle, testis, heart, kidney, lung, brain, pancreas, spleen and smooth muscle Poly A þ RNAs (Clontech) were used as templates. The first-strand cDNA was synthesized at 481C for 45 min, the template was denatured for 2 min and the second-strand cDNA was synthesized and amplified through 40 cycles (30 s at 941C, 1 min at 721C) followed by 5 min at 681C.
RNAse protection assay
Essentially, the protocol and kits for Ambion's RPAII kit were used. The only exception was the halving of the components and hence reaction volumes while generating the probes. Briefly, radiolabelled probes to the unique C-termini of CrkII and CrkIII were generated. These were 115 and 95 bases, respectively, which were inserted into the pBluescript II SK plasmid and transcribed in the presence of 32 P UTP. These probes were gel purified (7% acrylamide 7 m urea gel), counted and hybridized overnight in excess with 1 mg mouse polyA RNA (tissues and source as described previously). RNAse was then added to destroy any unhybridized RNA, the remaining RNA precipitated, resuspended and run on another 7% acrylamide, 7 m urea gel. The gel was then dried and exposed to film for 1-24 h.
In vitro transcription and translation
In vitro transcription and translation were performed using the TNT-Coupled Reticulocyte Lysate Systems kit from Promega. CrkII and CrkIII were both placed in the pcDNA 3.1 þ vector. Briefly, a single tube transcription and translation was performed in the presence of 35 S methionine and T7 polymerase. The resulting product was gel purified, fixed and autographed for 24 h.
Preparation of CrKIII and ERK antibodies
Rabbit polyclonal anti-CrkIII antibodies are directed against a peptide from the carboxyterminus of mouse CRKIII, unique for CrkIII. The peptide sequence CDLLQGLPFRPLPAL was coupled to keyhole limpet hemocyanine and was used for immunization. ERK antibodies were generated as per Wang Simonson Dunn, (1992) . Biochem. J., 287.
Construction and use of recombinant adenoviral vectors
Crk adenoviral constructs were constructed using the procedure detailed previously from Foschi et al. (1997) with the exception that the adenoviral CrkII construct was made by direct ligation and not homologous recombination. CrkII and CrkIII were both excised/ligated using Xba1 and Sal1 at 5 0 and 3 0 , respectively. Human mesangial cells were infected with MOIs of 60 for CrkII and 100 for CrkIII in RPMI containing 2% fetal bovine serum. After 1 h infection, the serum-free culture medium was returned to the plates. At 24 h after infection, the cells were stimulated with 0.86 mm insulin for the times indicated. Cells were then washed with ice-cold PBS and lysed in 50 mm HEPES buffer, pH 7.5, 150 mm NaCl, 10% glycerol, 1% Triton X-100, 1.5 mm MgCl 2 , 1 mm EGTA, 1 mm phenylmethylsulfonyl fluoride and 0.2 mm sodium orthovanadate containing the Complete protease inhibitor cocktail from Roche. Infection efficiency was measured by infecting with an adenovirus encoding green fluorescent protein, always infected at the lowest experimental MOI used. Infection efficiency in all experiments was approximately 100%.
Accession numbers
Accession number for CrkIII is AF239673.
